

Miguel Servet Researcher Position

The Molecular Oncology group (<http://bit.ly/molonco>) at Institut de Recerca Biomèdica de Lleida (IRB Lleida) is looking for a highly motivated candidate to apply for a tenure track researcher position funded by the 'Miguel Servet' Program of the Spanish Government through the Instituto de Salud Carlos III (<https://www.isciii.es/QueHacemos/Financiacion/solicitudes/Documents/AES%202023.pdf>).

The group strategic lines in the oncology field are:

- 1) Investigation of the molecular mechanisms underlying the initiation and progression of gastrointestinal tumors (colorectal and gastric) with the ultimate goal of improving the diagnosis and treatment of patients.
- 2) Personalization of the chemotherapeutic treatment in patients with colorectal cancer. Our laboratory has been interested for long time in identifying new molecular biomarkers capable of predicting the response of patients with colorectal cancer to the treatment with small molecule chemotherapeutic agents.

Required:

- Hold a PhD degree in biological or biomedical sciences obtained between January 2011 and December 2018 (with the exceptions listed in the call),
- Strong publication record in the field,
- Have professional experience in top national/international research institutions.
- Write a research project in the field of gastrointestinal cancer research.

Valued:

- Participation in research projects and mobility.
- Direction of graduate, master's and/or undergraduate students,
- Organizational, proactive and self-motivated attitude,
- Communication skills.

Offered:

- Full-time 5-year contract (3+2),
- Remuneration: 40.500€/year (gross annual salary),
- Institutional tenure track programme. IRB Lleida has established a tenure track programme to stabilize Miguel Servet researchers that upon their 5-year contract are positively evaluated by the Instituto de Salud Carlos III. After obtaining the tenure track position at our institute, the candidate will be evaluated every five years by the Scientific Council of Institut Català de la Salut. The result of the evaluation will determine whether the researcher is economically promoted or maintained in the same salary range. Eventually, if the result of the evaluation is not positive, specific actions will be put in place to assist the researcher to improve his/her scientific track in a given period of time and prevent the interruption of the contract.
- Skillful and social colleagues, a highly stimulating and dynamic scientific environment, state-of-the-art infrastructures, challenging tasks, wide range of responsibilities and unique professional career development opportunities.

Application Procedure:

IRB Lleida is a research center recognized by Instituto de Salud Carlos III. The number of applications for Miguel Servet positions is restricted to 5 for recognized institutes. Accordingly, an internal prioritization selection process will take place from April 4th to April 11th 2023 (see below).

The interested candidates in leading their own lines of research by joining the Molecular Oncology group and apply to the internal prioritization phase should apply before April 3rd 2023. All applications must be addressed by email to molecular.oncology@irbllleida.cat and include:

- A complete CV,
- A motivation letter,
- Contact details for reference.

Please, indicate MS2023-BC in the subject.

Selection Process:

- The group will select a candidate based on the CV, motivation letter, experience and personal interview.
- The selected candidate will apply to IRBLleida internal prioritization phase by addressing a letter of interest to the Institute Grants Office before April 4th 2023 (15:00h), and the application documents that will be provided before April 11th 2023 (15:00h).
- The internal prioritization process will be as follows:
 - 1) Assessment of the curricular merits of the candidates (eliminary phase).
 - 2) Personal interview. The candidates passing the eliminary phase will be interviewed to evaluate their interest in joining IRBLleida and their ability to generate collaborations and synergies with the Institute's research groups.

Provisional resolution of the prioritization process will be announced on April 14th 2023.

Final resolution of the prioritization process will be announced on April 17th 2023.

- The selected candidate by IRBLleida will apply for the position to Instituto Acreditado Carlos III before April 18th 2023 according to following guidelines: <https://www.isciii.es/QueHacemos/Financiacion/solicitudes/Paginas/default.aspx>.

The Institute:

IRBLleida acts as a cluster of all biomedical research carried out in Lleida and incorporates to two stakeholders that conduct health research and implement innovation policies:

- The University of Lleida (UdL) includes researchers from the Faculties of Medicine, Nursing and Physiotherapy.
 - The Department of Health, includes researchers from Arnau de Vilanova University Hospital (HUAV), Santa María University Hospital (HUSM), Catalan Health Institute (ICS) and Lleida Primary Care and Community.
- IRBLleida is a CERCA center, the biocluster supported and supervised by the Autonomous Government of Catalonia, and it is also accredited as a Centre of Excellence by Carlos III Health Institute (funded by Spanish Government).

We offer and promote a diverse and inclusive environment and welcome applicants regardless gender, nationality, ethnicity or religion. IRBLleida was awarded with the 'HR Excellence in Research' from the European Commission. This recognition reflects the commitment of IRBLleida recruitment and appraisal procedures in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers.

